Thomas J Lobl Selected Research

Neoplasms (Cancer)

4/2002

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas J Lobl Research Topics

Disease

2	Infections 01/2020 - 10/2018
1	Neoplasms (Cancer) 04/2002

Drug/Important Bio-Agent (IBA)

1	PolyestersIBA 01/2020
1	N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicinIBA 04/2002
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2002
1	ProdrugsIBA 04/2002

Therapy/Procedure

2	Catheters 01/2020 - 10/2018
2	Renal Dialysis (Hemodialysis) 01/2020 - 10/2018
1	Indwelling Catheters (Indwelling Catheter) 01/2020
1	Aftercare (After-Treatment) 04/2002
1	Therapeutics 04/2002